Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-98.78	-103.69	-89.02	-71.58	-37.66	-51.38
Depreciation & Amortization	0.29	0.04	0.74	-4.31	0.22	0.25
Stock-Based Compensation	34.62	34.02	20.17	12.91	3.19	3.85
Other Adjustments	0.47	0.46	-0.54	0.31	1.74	-
Changes in Accounts Payable	0.08	0.82	0.81	-2.25	0.41	0.39
Changes in Accrued Expenses	-2.47	-0.5	-0.25	7.66	1.61	0.39
Changes in Other Operating Activities	0.33	-1.44	-5.1	-4.01	-1.59	-0.27
Operating Cash Flow	-65.47	-70.3	-73.19	-61.27	-32.08	-46.77
Capital Expenditures	-0.14	-0.16	-0.04	-0.15	-0.61	-0.01
Sale of Property, Plant & Equipment	-	0.21	-	-	-	-
Purchases of Investments	-357.35	-350.74	-446.79	-268.26	-	-47.56
Proceeds from Sale of Investments	320.59	272.9	313.91	120	-	45.94
Other Investing Activities	-	-	0.87	-	-	-
Investing Cash Flow	-132.74	-173.84	-36	-148.41	-0.61	-1.63
Issuance of Common Stock	120.38	219.08	133.17	0.4	0.59	49.68
Net Common Stock Issued (Repurchased)	120.38	219.08	133.17	0.4	0.59	49.68
Other Financing Activities	-	-0.22	-	233.89	-2.39	-0.58
Financing Cash Flow	228.69	218.87	133.17	234.29	-1.8	49.1
Net Cash Flow	30.48	-25.28	23.98	24.61	-34.49	0.7
Free Cash Flow	-65.6	-70.46	-73.24	-61.42	-32.69	-46.78
Free Cash Flow Per Share	-1.10	-1.24	-1.56	-1.73	-10.46	-13.44
Levered Free Cash Flow	-100.69	-104.94	-92.87	-74.64	-37.62	-50.63
Unlevered Free Cash Flow	-117.64	-120.9	-108.67	-86.58	-38.75	-50.69

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q